These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
470 related items for PubMed ID: 24321400
1. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, Ottosen C, Soegaard CH, Soegaard-Andersen E, Hoegdall C. Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400 [Abstract] [Full Text] [Related]
2. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269 [Abstract] [Full Text] [Related]
3. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter? Markauskas A, Mogensen O, dePont Christensen R, Jensen PT. Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461 [Abstract] [Full Text] [Related]
4. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO. Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038 [Abstract] [Full Text] [Related]
5. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Luo Y, Lee M, Kim HS, Chung HH, Song YS. Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388 [Abstract] [Full Text] [Related]
6. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490 [Abstract] [Full Text] [Related]
8. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer]. Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH. Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524 [Abstract] [Full Text] [Related]
9. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C, Mi K, Zhu Y, Cheng J, Zha X. Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159 [Abstract] [Full Text] [Related]
10. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, Sartori E. Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700 [Abstract] [Full Text] [Related]
11. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727 [Abstract] [Full Text] [Related]
12. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845 [Abstract] [Full Text] [Related]
13. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306 [Abstract] [Full Text] [Related]
14. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. Pepin K, Bregar A, Davis M, Melamed A, Hinchcliff E, Gockley A, Horowitz N, Del Carmen MG. Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028 [Abstract] [Full Text] [Related]
16. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer]. Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW. Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313 [Abstract] [Full Text] [Related]
18. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. Nicklin JL, McGrath S, Tripcony L, Garrett A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, Nascimento M, Walker G, Sanday K, Obermair A. Aust N Z J Obstet Gynaecol; 2017 Dec 25; 57(6):651-658. PubMed ID: 28718942 [Abstract] [Full Text] [Related]